Discerning the clinical relevance of biomarkers in early stage breast cancer.

about

Discerning the clinical relevance of biomarkers in early stage breast cancer.

Item

http://www.wikidata.org/entity/Q38841237

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Discerning the clinical relevance of biomarkers in early stage breast cancer.

@en

type

Item

label

Discerning the clinical relevance of biomarkers in early stage breast cancer.

@en

prefLabel

Discerning the clinical relevance of biomarkers in early stage breast cancer.

@en

P1476

Discerning the clinical relevance of biomarkers in early stage breast cancer

@en

P2093

Bryan P Schneider

http://www.w3.org/2001/XMLSchema#string

Carol B White

http://www.w3.org/2001/XMLSchema#string

Elda Railey

http://www.w3.org/2001/XMLSchema#string

Fei Shen

http://www.w3.org/2001/XMLSchema#string

Guanglong Jiang

http://www.w3.org/2001/XMLSchema#string

Mary Lou Smith

http://www.w3.org/2001/XMLSchema#string

Nawal Kassem

http://www.w3.org/2001/XMLSchema#string

P2860

Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.

Using conjoint analysis to elicit preferences for health care

Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile.

Patient preferences for chemotherapies used in breast cancer.

Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199.

Weekly paclitaxel in the adjuvant treatment of breast cancer.

Conjoint Analysis Applications in Health - How are Studies being Designed and Reported?: An Update on Current Practice in the Published Literature between 2005 and 2008.

Conjoint analysis applications in health--a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force.

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.

Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure.

P2888

s10549-017-4238-0

P304

89-97

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-017-4238-0

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

164

http://www.w3.org/2001/XMLSchema#string

P50

Tarah J. Ballinger

John Howell

P577

2017-04-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084745312

http://www.w3.org/2001/XMLSchema#string

P698

28401365

http://www.w3.org/2001/XMLSchema#string

P921

biomarker